Literature DB >> 16198397

Treating ovarian cancer patients at the end of life: when should we stop?

Vivian E von Gruenigen, Barbara J Daly.   

Abstract

Entities:  

Mesh：

Year:  2005        PMID： 16198397     DOI： 10.1016/j.ygyno.2005.09.005

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN： 0090-8258            Impact factor:   5.482


× No keyword cloud information.
  4 in total

Review 1.  Contemporary quality of life issues affecting gynecologic cancer survivors.

Authors:  Jeanne Carter; Richard Penson; Richard Barakat; Lari Wenzel
Journal:  Hematol Oncol Clin North Am       Date:  2011-12-16       Impact factor: 3.722

2.  A clinical perspective on genetic counseling and testing during end of life care for women with recurrent progressive ovarian cancer: opportunities and challenges.

Authors:  Molly S Daniels; Jennifer K Burzawa; Amanda C Brandt; Kathleen M Schmeler; Karen H Lu
Journal:  Fam Cancer       Date:  2011-06       Impact factor: 2.375

3.  Hope, quality of life, and benefit from treatment in women having chemotherapy for platinum-resistant/refractory recurrent ovarian cancer: the gynecologic cancer intergroup symptom benefit study.

Authors:  Katrin M Sjoquist; Michael L Friedlander; Rachel L O'Connell; Merryn Voysey; Madeleine T King; Martin R Stockler; Amit M Oza; Kim Gillies; Julie K Martyn; Phyllis N Butow
Journal:  Oncologist       Date:  2013-10-09

4.  Impact of Recurrence of Ovarian Cancer on Quality of Life and Outlook for the Future.

Authors:  Nicoletta Colombo; Domenica Lorusso; Paolo Scollo
Journal:  Int J Gynecol Cancer       Date:  2017-07       Impact factor: 3.437
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.